Xavier Gitton

TL;DR: Treatment with subcutaneous canakinumab once every 8 weeks was associated with a rapid remission of symptoms in most patients with CAPS and evaluated therapeutic responses using disease-activity scores and analysis of levels of C-reactive protein (CRP) and serum amyloid A protein (SAA).

TL;DR: Lumiracoxib showed a three to four-fold reduction in ulcer complications compared with non-steroidal anti-inflammatory drugs without an increase in the rate of serious cardiovascular events, suggesting that lumiracxib is an appropriate treatment for patients with osteoarthritis.

TL;DR: The primary endpoint, including incidence of myocardial infarction, did not differ between lumiracoxib and either ibuprofen or naproxen, irrespective of aspirin use, suggesting that lumirACoxib is an appropriate treatment for patients with osteoarthritis, who are often at high cardiovascular risk and taking low-dose aspirin.

TL;DR: The addition of canakinumab 150 mg SC q4wk improves therapeutic responses among patients who have active RA despite stable treatment with methotrexate, and is associated with significantly more favorable responses at week 12 with respect to secondary endpoints.

TL;DR: This meta-analysis of all completed, randomized controlled trials (RCTs) of patients with osteoarthritis and rheumatoid arthritis found no evidence that lumiracoxib was associated with a significant increase in CV risk compared with naproxen, placebo, or all comparators.